Humacyte, Inc.

NASDAQ:HUMA

Biotechnology

Healthcare
$0.50 -3.35%

-$0.03 today

Market cap
$138.90M
Beta
2.46
P/E (TTM)
-1.9
EPS (TTM)
-$0.49
52W Low $0.55High $2.84

Volume 3.91M

Average 8.14M

HUMA Long-term Debt

Borrowings due after more than one year.

Humacyte, Inc.NASDAQ: HUMA

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt falls 44.5% from a year ago

Long-term debt stood at $35.87M at the end of Q1 FY2026, down 44.5% from a year earlier and up 1.2% from the prior quarter. Over 3 fiscal years it compounded at +20.3% a year.

Context

  • Long-term debt amounted to 32.4% of total assets at the end of Q1 FY2026, down 7.3 pp from a year earlier.
  • Long-term debt increased in 2 of the last 3 fiscal years.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -44.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.87M+1.2% QoQ
Last fiscal yearDec 2025
$35.44M-44.1% YoY
Year agoMar 2025
$64.67M-44.5% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-44.5%——
1 year-44.1%——
3-year CAGR+20.3%——
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
35.44M USD
Year-over-year change
-44.1%
4-year CAGR
+6.7%

Long-term Debt vs competitors

How HUMA compares with its peers on the latest reported figures

  • HUMA's Mar 2026 long-term debt of $35.87M is the 2nd highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -44.5% is the lowest of 3, against a peer median of +19.4%.
  • Long-term debt amounts to 32.4% of total assets for HUMA, versus a peer median of 0.0%.
HUMA Competitors Peer median
Long-term Debt for HUMA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$3.32B ——1.5%
HUMAHumacyte, Inc.Mar 2026$35.87M -44.5%+20.3%32.4%
NAUTNautilus Biotechnology, Inc.Mar 2026$25.02M ——14.1%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$19.68M +31.2%—8.0%
ACHVAchieve Life Sciences, Inc.Mar 2026$9.32M +7.7%—28.2%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
SGMTSagimet Biosciences Inc.Mar 2026$0 ——0.0%
VNDAVanda Pharmaceuticals Inc.Mar 2026$0 ——0.0%
TRDAEntrada Therapeutics, Inc.Mar 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.Mar 2026$0 ——0.0%
VYGRVoyager Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding HUMA) $0+19.4%—0.0%

Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents217.5M149.77M80.45M44.94M50.5M
Short-term Investments8M2.11M000
Net Receivables176K31K00441K
Inventory000013.59M
Other Current Assets02.3M2.83M2.92M3.27M
Total Current Assets229.34M154.21M83.28M47.86M67.8M
Property, Plant & Equipment (Net)57.19M50.09M44.1M38.55M47.69M
Goodwill00000
Intangible Assets00000
Long-term Investments0000209K
Tax Assets00000
Other Non-current Assets00841K51.46M672K
Total Non-current Assets57.19M50.09M44.95M90.01M48.57M
Total Assets286.53M204.3M128.22M137.87M116.37M
Account Payables2.09M1.6M6.49M4.49M5.4M
Short-term Debt08.57M000
Tax Payables173K0000
Deferred Revenue00000
Other Current Liabilities4.12M4.23M5.29M7.37M6.63M
Total Current Liabilities11.05M19.58M18.44M19.95M18.37M
Long-term Debt27.36M20.34M38.6M63.35M35.44M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities104.16M28.61M41.34M156.97M32.47M
Total Non-current Liabilities153.31M67.79M96.23M170.59M94.89M
Total Liabilities164.36M87.37M114.68M190.54M113.26M
Common Stock10K10K10K13K20K
Retained Earnings(414.57M)(426.54M)(537.31M)(686.02M)(726.85M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity122.17M116.93M13.55M(52.67M)3.11M
Total Debt51.18M50.07M57.45M16.54M64.85M
Net Debt(166.32M)(99.71M)(23M)(28.4M)14.35M

Humacyte, Inc.

NASDAQ:HUMA

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.